Prescription drug · ANDA
Metoprolol Succinate NDC 62207-131
Metoprolol succinate 100 mg/1 · Tablet, Extended release · Oral · Granules India Ltd
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 62207-131-49 | 62207013149 | 1000 TABLET, EXTENDED RELEASE in 1 BOTTLE (62207-131-49)Marketed from Aug 16, 2024 | |
| 62207-131-54 | 62207013154 | 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (62207-131-54)Marketed from Aug 16, 2024 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Metoprolol Succinate
- Generic name (nonproprietary)
- metoprolol succinate
- Active ingredients
- Metoprolol succinate — 100 mg/1
- Dosage form
- Tablet, Extended release
- Route
- Oral
- Labeler
- Granules India Ltd
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 216509
- Marketing start
- Listing expires
- Other FDA classes
- Adrenergic beta-Antagonists (Mechanism)
- Identifiers
- Product ID 62207-131_5aa3c876-3d09-cea0-e063-6294a90a0e70SPL ID 5aa3c876-3d09-cea0-e063-6294a90a0e70SPL set ID c5431c8a-d92c-489e-b63b-4b9cc8f32a1aRxCUI 866412, 866419, 866427, 866436UNII TH25PD4CCBUPC 0362207133548, 0362207130547, 0362207132541
- Pharmacologic class
- beta-Adrenergic Blocker
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N462207013149followed by a unit qualifier and the quantityPackage 62207-0131-49. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
Metoprolol succinate is a beta-adrenergic blocker indicated for the treatment of: Hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Angina Pectoris. ( 1.2 ) Heart Failure, to reduce the risk of cardiovascular mortality and heart failure hospitalizations in patients with heart failure ( 1.3 ) 1.1 Hypertension Metoprolol succinate extended-release tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These be…
Excerpt only. Read the full label for complete information.
Other NDCs under ANDA 216509
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Metoprolol Succinate | Metoprolol succinate 50 mg/1 | Tablet, Extended releaseOral | Granules India Ltd | 62207-133 |
| Metoprolol Succinate | Metoprolol succinate 25 mg/1 | Tablet, Extended releaseOral | Granules India Ltd | 62207-130 |
| Metoprolol Succinate | Metoprolol succinate 200 mg/1 | Tablet, Extended releaseOral | Granules India Ltd | 62207-132 |